Research Test Tubes Science Adobestock 63575703

Developing new ways to target prostate cancer which do not respond to treatment

20220127 Bevan Charlotte 2
Professor Charlotte Bevan

Grant information

Institution - Imperial College London
Researcher - Professor Charlotte Bevan
Grant award - £99,155
Duration of funding - 2013-2016
Status - Complete
Reference - S12-026

It’s the belief that what we're doing is going to improve things for men – perhaps not now, maybe not soon; but eventually.
Professor Charlotte Bevan Imperial College London

The project in a nutshell

20230301 Charlotte Bevan team member plate
Researcher in Professor Charlotte Bevan's team
  • The team have designed and tested a new treatment, known as a microrepressor, to target the androgen receptor (AR), a key driver of prostate cancer progression.
  • This new therapeutic approach reduced the activity of the AR and appeared to enhance the effect of other therapies in targeting hormone-resistant prostate cancer cells.
  • Further work is currently underway to refine the delivery of the microrepressors, before hopefully moving towards clinical trials.

Why did we fund this project?

  • Androgens such as testosterone are important in the growth of prostate cancer.
  • These androgens bind to and activate the androgen receptor (AR), with many current therapies designed to target either the production of androgens or activity of the AR.
  • Hormone therapy targets androgens, and some men with prostate cancer can become resistant to hormone therapy, which leads to the return of aggressive prostate cancer.
  • Therefore, better methods of targeting the AR are required to prevent resistance and relapse.
  • This project proposes a new way to block the AR which can overcome limitations of hormone-resistant prostate cancer of current therapies.
Spotlight on - The AR

What did the team do?

20230301 Charlotte Bevan team member workbench
Researcher in Professor Charlotte Bevan's team
  • The team checked whether the microrepressors are specific to the androgen receptor (AR).
  • The team used advanced microscopy techniques to see if microrepressors stop the movement and activity of the AR.
  • The team also investigated whether the microrepressors can be combined with other anti-androgen therapies.

What did the team achieve?

20230301 Charlotte Bevan team
Professor Charlotte Bevan and the team
  • The team showed that in the presence of androgens, the microrepressors can attach to the androgen receptor (AR) and reduce its activity.
  • When combined, the microrepressors showed promise in enhancing the effects of other anti-androgen therapies on reducing prostate cancer growth.
  • The team were able to show that the microrepressors were selective to the AR, which means they are specific and will limit potential side effects.

How will this benefit men?

Cheer Family Dad Grandad Sofa Adobestock 289723739
  • Current therapies are relatively limited for men with hormone-resistant prostate cancer, and they can have adverse side-effects to men.
  • These microrepressors could be used to enhance current anti-androgen therapies to reduce prostate cancer growth.
  • So, this study is an important step in finding new ways to target hormone-resistance, increasing life-expectancy and quality of life for men.

With your help we can beat prostate cancer, together

With your continued support you can help us cure more men with less harm. Take action today and help us work towards a future where men's lives aren't limited by prostate cancer

Join the fight